CTLA4 and neoplasm: PD-1 is now considered a better target than CTLA-4 because antibody-mediated blockade of PD-1 among tumor-infiltrating T cells within the tumor microenvironment leads to mitigated side effects and higher response rates [107], especially among patients with PD-L1 positive tumors [6,108].